NM
TBPH icon

Newtyn Management’s Theravance Biopharma TBPH Stock Holding History

Newtyn Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.4M Sell
3,434,191
-1,407,438
-29% -$23.3M 7.29% 2
2026
Q1 		$78.6M Buy
4,841,629
+541,629
+13% +$9.58M 8.4% 2
2025
Q4 		$80.5M Sell
4,300,000
-650,000
-13% -$10.8M 8.45% 5
2025
Q3 		$72.3M Hold
4,950,000
– – 8.85% 3
2025
Q2 		$54.6M Buy
4,950,000
+192,597
+4% +$1.87M 8.27% 2
2025
Q1 		$42.5M Hold
4,757,403
– – 6.72% 6
2024
Q4 		$44.8M Buy
4,757,403
+258,337
+6% +$2.35M 7.8% 3
2024
Q3 		$36.3M Buy
4,499,066
+2,374,363
+112% +$20.6M 5.57% 5
2024
Q2 		$18M Buy
2,124,703
+480,773
+29% +$4.34M 3.38% 12
2024
Q1 		$14.7M Sell
1,643,930
-256,070
-13% -$2.37M 2.94% 12
2023
Q4 		$21.4M Buy
1,900,000
+58,440
+3% +$588K 4.19% 7
2023
Q3 		$15.9M Buy
1,841,560
+201,104
+12% +$1.94M 3.92% 9
2023
Q2 		$17M Buy
1,640,456
+109,441
+7% +$1.21M 4.01% 10
2023
Q1 		$16.6M Buy
1,531,015
+81,015
+6% +$857K 3.26% 7
2022
Q4 		$16.3M Sell
1,450,000
-1,045,860
-42% -$11M 3.36% 10
2022
Q3 		$25.3M Buy
2,495,860
+458,035
+22% +$4.29M 5.56% 5
2022
Q2 		$18.5M Buy
2,037,825
+662,825
+48% +$6.11M 3.5% 10
2022
Q1 		$13.1M Buy
1,375,000
+375,000
+38% +$3.67M 3.15% 14
2021
Q4 		$11.1M Buy
1,000,000
+902,045
+921% +$7.86M 2.93% 17
2021
Q3 		$725K Buy
+97,955
New +$1.1M 0.19% 36
2020
Q1 		– Sell
-173,300
Closed -$4.49M – 61
2019
Q4 		$4.49M Buy
173,300
+109,619
+172% +$2.13M 0.41% 36
2019
Q3 		$1.24M Buy
+63,681
New +$1.29M 0.12% 40

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Newtyn Management's TBPH Position: Q2 2026 in Review

Newtyn Management reduced its Theravance Biopharma (TBPH) stake by 29% in Q2 2026, selling an estimated $23.3M and leaving 3,434,191 shares worth $58.4M. The position accounts for 7.29% of the portfolio, ranked #2.

Newtyn Management first reported a position in TBPH in Q3 2019 and has held it in 22 quarters since. The position peaked at $80.5M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Newtyn Management held 3,434,191 shares of Theravance Biopharma worth $58.4M as of Q2 2026.
  • Newtyn Management sold 1,407,438 Theravance Biopharma shares in Q2 2026, an estimated $23.3M.
  • Theravance Biopharma made up 7.29% of Newtyn Management's portfolio in Q2 2026, its #2 holding.
  • Newtyn Management first reported a position in Theravance Biopharma in Q3 2019 and has held it in 22 quarters since.
  • Newtyn Management's Theravance Biopharma position peaked at $80.5M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Newtyn Management's 13F filing for Q2 2026, filed 14 Aug 2026.